Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...

Biosion inks exclusive, global license pact with Aclaris Therapeutics on two potential first-in-class and best-in-class immunology assets: Newark, Delaware Wednesday, November 20, ...

Aclaris stock surges on inking an exclusive license agreement with Biosion for global rights to two of the latter's pipeline candidates, BSI-045B and BSI-502.

BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...

Biosion, Inc., a R&D stage biotechnology company, announced Monday that it has entered into an exclusive license agreement with ...

Biosion Inc. is getting more than $40 million in cash up front from Aclaris Therapeutics Inc. for the rights to develop two antibodies. The regulatory and sales milestones could also bring Biosion ...

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

Under the agreement, Biosion will receive over $40 million cash as an upfront license fee and reimbursement for certain development costs and drug product materials. Biosion said it will receive 19.9% ...

Aclaris Therapeutics (ACRS) has entered into an exclusive license agreement with Biosion for worldwide rights to BSI-045B, a potential best-in-class, clinical-stage, novel anti-TSLP monoclonal ...

BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired full ex-China rights to an anti-TSLP humanized mAb and ...